Table 3.

Unadjusted regression models of androgen levels and 12- and 36-month outcomes within each sex

Androgensa	Infant sex	Outcomes
		12-month AOSI			36-month SRS
		Beta	95% CI	P	Beta	95% CI	P
ln(T)	Female (n = 62)	0.20	(−0.12,0.51)	0.22	−0.06	(−0.30,0.19)	0.64
	Male (n = 75)	0.20	(−0.13,0.52)	0.23	0.05	(−0.25,0.36)	0.73
ln(A4)	Female (n = 62)	0.06	(−0.36,0.48)	0.78	−0.18	(−0.50,0.14)	0.26
	Male (n = 75)	0.06	(−0.33,0.45)	0.76	−0.21	(−0.57,0.15)	0.24
ln(DHEA)	Female (n = 62)	0.09	(−0.19,0.37)	0.51	−0.05	(−0.25,0.16)	0.67
	Male (n = 75)	0.04	(−0.28,0.34)	0.82	−0.01	(−0.31,0.29)	0.94

ln natural log transformed

^aSeparate robust regression models of log_e-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total log_e (AOSI + 1) and log_e (SRS raw) scores. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and 36-month Social Responsiveness Scale (SRS) total raw score